{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:47:48Z","timestamp":1784238468499,"version":"3.55.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>There are two fairly common complications during pregnancy, i.e., gestational diabetes mellitus (GDM) and pre-eclampsia, which are independent, but are also closely linked in prevalence in pregnant women, with potential serious adverse consequences. IL-37 and IL-38, which belong to the IL-1 superfamily, participate in anti-inflammatory responses. Dysregulation of IL-37 and IL-38 has been observed in many auto-immune diseases. IL-37 is substantially reduced in the umbilical cords and placentas of GDM subjects, but IL-37 is significantly induced in the placentas of pre-eclampsia patients, suggesting there are differential regulatory roles of IL-37 in obstetrics, despite IL-37 being an anti-inflammatory mediator. Furthermore, IL-38 is substantially increased in the umbilical cords and placentas of GDM subjects, but minimal difference is observed in the placentas from pre-eclampsia patients. These data imply that IL-38 is also regulated independently within the diseased placentas. This review provides some insight for both basic scientists and medical practitioners to manage these patients effectively.<\/jats:p>","DOI":"10.3389\/fmed.2021.737084","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T09:43:04Z","timestamp":1630662184000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["The Role of IL-37 and IL-38 in Obstetrics Abnormalities"],"prefix":"10.3389","volume":"8","author":[{"given":"Mei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.0001-6349.2005.00634.x","article-title":"Period of gestational diabetes mellitus diagnosis and maternal and fetal morbidity","volume":"84","author":"Barahona","year":"2005","journal-title":"Acta Obstet Gynecol Scand."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.ijgo.2008.11.025","article-title":"Future risk of diabetes in mother and child after gestational diabetes mellitus","volume":"104","author":"Damm","year":"2009","journal-title":"Int J Gynaecol Obstet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11892-015-0579-4","article-title":"Preeclampsia and diabetes","volume":"15","author":"Weissgerber","year":"2015","journal-title":"Curr Diab Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/ijms22084261","article-title":"Gestational diabetes mellitus and maternal immune dysregulation: what we know so far","volume":"22","author":"McElwain","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1530\/EC-19-0436","article-title":"IL-34 causes inflammation and beta cell apoptosis and dysfunction in gestational diabetes mellitus","volume":"8","author":"Piao","year":"2019","journal-title":"Endocr Connect."},{"key":"B6","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/cei.12608","article-title":"Interleukin-1 family cytokines and their regulatory proteins in normal pregnancy and pre-eclampsia","volume":"181","author":"Southcombe","year":"2015","journal-title":"Clin Exp Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2337\/dc18-2021","article-title":"Hyperglycemia and adverse pregnancy outcome follow-up study (HAPO FUS): maternal glycemia and childhood glucose metabolism","volume":"42","author":"Scholtens","year":"2019","journal-title":"Diabetes Care."},{"key":"B8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.diabres.2013.10.012","article-title":"Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization Guideline","volume":"103","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"B9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/dme.12381","article-title":"Trying to understand gestational diabetes","volume":"31","author":"Catalano","year":"2014","journal-title":"Diabet Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/oby.2008.307","article-title":"Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test","volume":"16","author":"Retnakaran","year":"2008","journal-title":"Obesity."},{"key":"B11","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/0002-9378(85)90665-9","article-title":"Dynamics of human chorionic gonadotropin, prolactin, and growth hormone in serum and amniotic fluid throughout normal human pregnancy","volume":"151","author":"Kletzky","year":"1985","journal-title":"Am J Obstet Gynecol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat Rev Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1007\/s00125-005-1764-9","article-title":"An immune origin of type 2 diabetes?","volume":"48","author":"Kolb","year":"2005","journal-title":"Diabetologia."},{"key":"B14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0140-6736(10)60279-6","article-title":"Pre-eclampsia","volume":"376","author":"Steegers","year":"2010","journal-title":"Lancet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1161\/HYPERTENSIONAHA.117.09246","article-title":"All hypertensive disorders of pregnancy increase the risk of future cardiovascular disease","volume":"70","author":"Tooher","year":"2017","journal-title":"Hypertension."},{"key":"B17","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.placenta.2008.11.021","article-title":"Placental stress and pre-eclampsia: a revised view","volume":"30","author":"Redman","year":"2009","journal-title":"Placenta."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.revmed.2011.03.331","article-title":"Preeclampsia: a multi-stress disorder","volume":"32","author":"Redman","year":"2011","journal-title":"Rev Med Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ni1110-973","article-title":"IL-1 family nomenclature","volume":"11","author":"Dinarello","year":"2010","journal-title":"Nat Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.1944","article-title":"IL-37 is a fundamental inhibitor of innate immunity","volume":"11","author":"Nold","year":"2010","journal-title":"Nat Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1684\/ecn.2011.0288","article-title":"IL-37: a new anti-inflammatory cytokine of the IL-1 family","volume":"22","author":"Boraschi","year":"2011","journal-title":"Eur Cytokine Netw."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/cyto.2000.0799","article-title":"IL-1H, an interleukin 1-related protein that binds IL-18 receptor\/IL-1Rrp","volume":"13","author":"Pan","year":"2001","journal-title":"Cytokine."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1074\/jbc.275.2.1169","article-title":"Four new members expand the interleukin-1 superfamily","volume":"275","author":"Smith","year":"2000","journal-title":"J Biol Chem."},{"key":"B24","doi-asserted-by":"publisher","first-page":"15178","DOI":"10.1073\/pnas.1416714111","article-title":"Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells","volume":"111","author":"Luo","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/imr.12605","article-title":"Suppression of inflammation and acquired immunity by IL-37","volume":"281","author":"Cavalli","year":"2018","journal-title":"Immunol Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"6691","DOI":"10.2147\/CMAR.S200627","article-title":"IL-37 induces anti-tumor immunity by indirectly promoting dendritic cell recruitment and activation in hepatocellular carcinoma","volume":"11","author":"Liu","year":"2019","journal-title":"Cancer Manag Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.bbalip.2019.05.009","article-title":"IL-37 inhibits the maturation of dendritic cells through the IL-1R8-TLR4-NF-\u03baB pathway","volume":"1864","author":"Liu","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids."},{"key":"B28","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.4049\/jimmunol.1401810","article-title":"IL-37 alleviates rheumatoid arthritis by suppressing IL-17 and IL-17\u2013triggering cytokine production and limiting Th17 cell proliferation","volume":"194","author":"Ye","year":"2015","journal-title":"J Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"136329","DOI":"10.1155\/2014\/136329","article-title":"The possible role of the novel cytokines il-35 and il-37 in inflammatory bowel disease","volume":"2014","author":"Li","year":"2014","journal-title":"Mediat Inflamm."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1159\/000487344","article-title":"Transgenic overexpression of IL-37 protects against atherosclerosis and strengthens plaque stability","volume":"45","author":"Liu","year":"2018","journal-title":"Cell Physiol Biochem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1006\/bbrc.1999.1440","article-title":"IL1HY1: a novel interleukin-1 receptor antagonist gene","volume":"263","author":"Mulero","year":"1999","journal-title":"Biochem Biophys Res Commun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.4049\/jimmunol.167.3.1440","article-title":"Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2","volume":"167","author":"Debets","year":"2001","journal-title":"J Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s12551-020-00726-0","article-title":"IL-34, IL-36 and IL-38 in colorectal cancer-key immunoregulators of carcinogenesis","volume":"12","author":"Bao","year":"2020","journal-title":"Biophys Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/jmcb\/mjw006","article-title":"Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses","volume":"8","author":"Mora","year":"2016","journal-title":"J Mol Cell Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/s41419-018-1143-3","article-title":"IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment","volume":"9","author":"Mercurio","year":"2018","journal-title":"Cell Death Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/imr.12612","article-title":"Biology of IL-38 and its role in disease","volume":"281","author":"van de Veerdonk","year":"2018","journal-title":"Immunol Rev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"5140691","DOI":"10.1155\/2018\/5140691","article-title":"Differential expression of IL-36 family members and IL-38 by immune and nonimmune cells in patients with active inflammatory bowel disease","volume":"2018","author":"Fonseca-Camarillo","year":"2018","journal-title":"BioMed Res Int."},{"key":"B39","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.bbrep.2015.10.015","article-title":"IL-38: a new factor in rheumatoid arthritis","volume":"4","author":"Takenaka","year":"2015","journal-title":"Biochem Biophys Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"490120","DOI":"10.1155\/2015\/490120","article-title":"Elevated plasma IL-38 concentrations in patients with acute ST-segment elevation myocardial infarction and their dynamics after reperfusion treatment","volume":"2015","author":"Zhong","year":"2015","journal-title":"Mediat Inflamm."},{"key":"B41","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.intimp.2016.09.023","article-title":"IL-38 alleviates concanavalin A-induced liver injury in mice","volume":"40","author":"Yuan","year":"2016","journal-title":"Int Immunopharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.placenta.2014.11.019","article-title":"Galectin-13\/PP-13 expression in term placentas of gestational diabetes mellitus pregnancies","volume":"36","author":"Unverdorben","year":"2015","journal-title":"Placenta."},{"key":"B43","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1038\/ncomms5711","article-title":"IL-37 protects against obesity-induced inflammation and insulin resistance","volume":"5","author":"Ballak","year":"2014","journal-title":"Nat Commun."},{"key":"B44","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2174\/1566524014666140414210831","article-title":"A possible role for interleukin 37 in the pathogenesis of Behcet's disease","volume":"14","author":"Ye","year":"2014","journal-title":"Curr Mol Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jri.2017.09.011","article-title":"IL-37 and 38 signalling in gestational diabetes","volume":"124","author":"Yu","year":"2017","journal-title":"J Reprod Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/exd.13228","article-title":"IL-36\u03b3 has proinflammatory effects on human endothelial cells","volume":"26","author":"Bridgewood","year":"2017","journal-title":"Exp Dermatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.4049\/jimmunol.1301481","article-title":"IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin","volume":"192","author":"Foster","year":"2014","journal-title":"J Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cyto.2016.05.023","article-title":"IL-36 receptor is expressed by human blood and intestinal T lymphocytes and is dose\u2013dependently activated via IL-36\u03b2 and induces CD4+ lymphocyte proliferation","volume":"85","author":"Penha","year":"2016","journal-title":"Cytokine."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e13785","DOI":"10.1097\/MD.0000000000013785","article-title":"Sudden seizure during cesarean section: a case report","volume":"97","author":"Zhou","year":"2018","journal-title":"Medicine."},{"key":"B50","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/annrheumdis-2016-210630","article-title":"IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro","volume":"76","author":"Boutet","year":"2017","journal-title":"Ann Rheumat Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom9080345","article-title":"IL-38: a new player in inflammatory autoimmune disorders","volume":"9","author":"Xie","year":"2019","journal-title":"Biomolecules."},{"key":"B52","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.archoralbio.2016.08.012","article-title":"Clinical periodontal status and inflammatory cytokines in gestational diabetes mellitus","volume":"72","author":"Ozcaka","year":"2016","journal-title":"Arch Oral Biol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12885-020-6587-z","article-title":"IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?","volume":"20","author":"Chen","year":"2020","journal-title":"BMC Cancer."},{"key":"B54","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00262-019-02440-7","article-title":"Interleukin-38 in colorectal cancer: a potential role in precision medicine","volume":"69","author":"Chen","year":"2020","journal-title":"Cancer Immunol Immunother."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.737084\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T09:43:07Z","timestamp":1630662187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.737084\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":54,"alternative-id":["10.3389\/fmed.2021.737084"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.737084","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,27]]},"article-number":"737084"}}